{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Edelman MJ"],"funding":["NCI NIH HHS"],"pagination":["189-94"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4890680"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(2)"],"pubmed_abstract":["Purpose
Overexpression of COX-2 correlates with advanced stage and worse outcomes in non-small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2-dependent prostaglandin E2 (PGE2). Exploratory analyses of studies that used COX-2 inhibitors have demonstrated potentially superior outcome in patients in whom the urinary metabolite of PGE2 (PGE-M) is suppressed. We hypothesized that patients with disease defined by PGE-M suppression would benefit from the addition of apricoxib to second-line docetaxel or pemetrexed.Patients and methods
Patients with NSCLC who had disease progression after one line of platinum-based therapy, performance status of 0 to 2, and normal organ function were potentially eligible. Only patients with a ≥ 50% decrease in urinary PG"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer."],"pmcid":["PMC4890680"],"funding_grant_id":["P30 CA134274"],"pubmed_authors":["Edelman MJ","Schneider BJ","Tan MT","Otterson G","Rogers JS","Fidler MJ","Sanborn RE","Sequist LV","Yang Y","Feliciano J","Keresztes R","Evans TL","Medeiros M","Zaknoen SL","de Mayolo JA"],"additional_accession":[]},"is_claimable":false,"name":"Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.","description":"Purpose
Overexpression of COX-2 correlates with advanced stage and worse outcomes in non-small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2-dependent prostaglandin E2 (PGE2). Exploratory analyses of studies that used COX-2 inhibitors have demonstrated potentially superior outcome in patients in whom the urinary metabolite of PGE2 (PGE-M) is suppressed. We hypothesized that patients with disease defined by PGE-M suppression would benefit from the addition of apricoxib to second-line docetaxel or pemetrexed.Patients and methods
Patients with NSCLC who had disease progression after one line of platinum-based therapy, performance status of 0 to 2, and normal organ function were potentially eligible. Only patients with a ≥ 50% decrease in urinary PG","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jan","modification":"2026-05-30T00:37:21.828Z","creation":"2019-03-27T02:15:08Z"},"accession":"S-EPMC4890680","cross_references":{"pubmed":["25452446"],"doi":["10.1200/JCO.2014.55.5789","10.1200/jco.2014.55.5789"]}}